Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases (Q28294789)

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

1 reference

7 January 2021

Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Regulation of mast cell survival by IgE

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

CD21 is a ligand for CD23 and regulates IgE production

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Cytokine modulators as novel therapies for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

1 reference

7 January 2021

Allergen sensitization through the skin induces systemic allergic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergic reactions to workplace allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Suppression of polyclonal human B cell activation by IgG binding factors: interference with the maturation of Ig-containing cells into Ig-secreting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Mast-cell responses in the development of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Rhinitis symptoms and IgE sensitization as risk factors for development of later allergic rhinitis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Fatalities following allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Mast cells: a unique and functional diversity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Association of asthma with serum IgE levels and skin-test reactivity to allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-immunoglobulin E (omalizumab) therapy in allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunologic aspects of schistosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunoglobulin E and effector cells in schistosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunity to schistosomes: progress toward vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-idiotype antibody-dependent cell-mediated cytotoxicity (ADCC) against idiotype-bearing cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Surface immunoglobulins as targets for anti-immunoglobulin-dependent cell-mediated lysis of B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Therapeutic strategies for allergic airways diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The pharmacological basis of anti-IgE therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-IgE as a mast cell-stabilizing therapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

1 reference

7 January 2021

Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The alliance of genes and environment in asthma and allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Can anti-IgE be used to treat allergy?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Structure and function of the B cell antigen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Regulation of the human IgE response by IL4 and IL13.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Activation-induced cell death in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Characterization of an anaphylactoid reaction to omalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE-mediated natural rubber latex allergy: practical considerations for health care workers.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The discovery of cromolyn sodium and its effect on research and practice in allergy and immunology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Prevalence of IgE-mediated food allergy among children with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Schistosoma mansoni infection in IgE-producing and IgE-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Occupational asthma and rhinoconjunctivitis induced by natural rubber latex exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunology. Isomeric antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Crystal structure of the human high-affinity IgE receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE enhances antibody and T cell responses in vivo via CD23+ B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Population disparities in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The biology of IGE and the basis of allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella spiralis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergen-specific IgE and IL-5 are essential for the development of airway hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Severe asthma treatment: need for characterising patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The structure of human CD23 and its interactions with IgE and CD21.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Risk factors and costs associated with an asthma attack

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Molecular and cellular targets of anti-IgE antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The allergy epidemic extends beyond the past few decades

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Antibody multispecificity mediated by conformational diversity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Raised levels of a new immunoglobulin class (IgND) in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

An increased frequency of IgE‐producing B cell precursors contributes to the elevated levels of plasma IgE in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Regulation of mast-cell and basophil function and survival by IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Basis of the 1:1 stoichiometry of the high affinity receptor FcεRI-IgE complex

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

CD23 trimers are preassociated on the cell surface even in the absence of its ligand, IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Structure and biology of stinging insect venom allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE- and IgE+Ag-mediated mast cell migration in an autocrine/paracrine fashion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Unexpected functions of FcepsilonRI on antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Failure of omalizumab for treatment of severe adult atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Drastic up-regulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Treatment of recalcitrant atopic dermatitis with omalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab is effective in the long-term control of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Extraordinarily high serum IgE levels and consequences for atopic phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab improves asthma-related quality of life in children with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Isolated late asthmatic reaction after exposure to a high-molecular-weight occupational agent, subtilisin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Role of IgE in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Cellular and immunologic mechanisms in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Effect of anti-IgE therapy in patients with peanut allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Effect of omalizumab in health care workers with occupational latex allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects☆☆☆★Results from the European Community Respiratory Health Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial cells and its role in food allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Reconstructing immune phylogeny: new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Truly MASTerful cells: mast cells command B cell IgE synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergy in long-term hemodialysis. II. Allergic and atopic patterns of a population of patients undergoing long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Loss of receptors and IgE in vivo during treatment with anti-IgE antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Upregulation of FcϵRI on human basophils by IgE antibody is mediated by interaction of IgE with FcϵRI☆☆☆★

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE receptors on human basophils. Relationship to serum IgE concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Maintenance of serum antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Negative signaling in B cells by surface immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The receptor with high affinity for immunoglobulin E.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Human mast cell proteases and mast cell heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Correlations between allergen-specific IgE serum levels in patients with allergic conjunctivitis in spring

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Advances in upper airway diseases and allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Regulation of B-cell fate by antigen-receptor signals

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergic and nonallergic forms of atopic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immune mechanisms leading to atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Unraveling the mission of FcepsilonRI on antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE in asthma and atopy: cellular and molecular connections

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE regulation and roles in asthma pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Monomeric IgE stimulates NFAT translocation into the nucleus, a rise in cytosol Ca2+, degranulation, and membrane ruffling in the cultured rat basophilic leukemia-2H3 mast cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The heterogeneity of mast cell tryptase from human lung and skin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

A quantitative approach for studying IgE-FcepsilonRI aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunity to helminths: is too much IgE parasite--rather than host-protective?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Function of CD23 in the response of human B cells to antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgE and non-IgE food allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergic rhinitis: epidemiology and natural history.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Mediators of immediate hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Regulation of plasma-cell development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Rush immunotherapy: experience with a one-day schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgG4 and IgE antibodies in atopic dermatitis and urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The natural history of peanut allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Persistent IgE synthesis in the nasal mucosa of hay fever patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immunoglobulins in tears and sera in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Rationale for new treatments aimed at IgE immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Omalizumab for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergens and natural rubber proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Antigen-independent induction of histamine synthesis by immunoglobulin E in mouse bone marrow-derived mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Ca2+ influx-mediated histamine synthesis and IL-6 release in mast cells activated by monomeric IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Peripheral deletion of rheumatoid factor B cells after abortive activation by IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Mechanisms of immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

CD23-mediated IgE transport across human intestinal epithelium: inhibition by blocking sites of translation or binding.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The crystal structure of IgE Fc reveals an asymmetrically bent conformation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

IgY: clues to the origins of modern antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Immune defense and eosinophilia in congenitally IgE-deficient SJA/9 mice infected with Angiostrongylus costaricensis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Allergic and latex-specific sensitization: route, frequency, and amount of exposure that are required to initiate IgE production

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

The diverse potential effector and immunoregulatory roles of mast cells in allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Production of recombinant protein therapeutics in cultivated mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Structural changes in the lectin domain of CD23, the low-affinity IgE receptor, upon calcium binding

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Agents against cytokine synthesis or receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Development of nasal basophilic cells and nasal eosinophils from age 4 months through 4 years in children of atopic parents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

Conformations of IgE bound to its receptor Fc epsilon RI and in solution

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2993002-8

7 January 2021

10.1016/S0065-2776(06)93002-8

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

17383539

1 reference

Consolidated OpenCitations Corpus – April 2017